Phagos

📍 Suresnes, France🗓 Founded 2021👥 75 employees💰 Last funded Jan 2025
Biotechnology Research🌐 phagos.com
Website LinkedIn
We are facing a global crisis where bacterial infections are becoming increasingly deadly due to antibiotic resistance. The health and economic consequences are staggering, with bacterial disease predicted to be the #1 cause of death by 2050. Alternatives are urgently needed, but nature already has its solution: phages, the natural predators of bacteria. At Phagos, we are bringing back phage technology by combining advances in microbiology with cutting-edge artificial intelligence. Our patented technology makes large-scale, customized phage-based veterinary medicines possible for the first time. And soon well universalize the technology for human health too. Our mission is to end bacterial disease.
4
Total investors
1
Early stage
3
Mid stage
0
Late stage
2021
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
France
2
United Kingdom
1
Greece
1
Investor activity2022–2025 · investors recorded per year
202212024220251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Phagos?
Phagos has 4 investors on record on gritt.io, including 1 early-stage backers, 3 mid-stage.
When did Phagos last raise funding?
The most recent investment in Phagos recorded on gritt.io was in January 2025.
When was Phagos founded?
Phagos was founded in 2021.
What industry is Phagos in?
Phagos operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Phagos based?
Phagos is headquartered in Suresnes, France.